In patients with unresectable HCC, outcomes with atezolizumab plus bevacizumab are not improved by the addition of low-dose ipilimumab.

The combination of pembrolizumab and EVX-01, a personalized peptide-based neoantigen cancer vaccine, demonstrated activity in patients with advanced melanoma, according to phase 2 study results.

Adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, improved PFS in patients with platinum-resistant, recurrent ovarian cancer in a phase 3 trial.

Adding EV and pembrolizumab to surgical treatment can improve outcomes in MIBC patients who are ineligible for cisplatin, data suggest.

Administering durvalumab before and after CRT did not provide a benefit over CRT alone in a phase 3 trial of patients with intermediate- and high-risk oropharyngeal cancer.

Adding nimotuzumab to post-surgery adjuvant cisplatin-based chemoradiotherapy does not improve survival outcomes in patients with HNSCC.

Data from a phase 1/2 study support the use of sevabertinib in patients with HER2-mutated NSCLC, an investigator says.

Tiragolumab plus atezolizumab does not improve survival compared to durvalumab in locally advanced, unresectable, stage 3 NSCLC.

This article was originally published on Stateline. In a clear rebuke of recent federal health policy, 15 Democratic governors announced Wednesday they’ve formed a public health alliance that breaks ...

In TNBC, pembrolizumab at a tenth of the current standard dose, plus chemotherapy, increased pCR compared to chemotherapy alone.

For patients with advanced or metastatic RCC, fruquintinib plus sintilimab improves PFS compared to investigator’s choice of axilitinib or everolimus.

Adding abemaciclib to endocrine therapy improved overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer.